Daniel A. Ermann

Primary Thyroid Lymphoma: An Analysis of the National Cancer Database

Victoria A. Vardell, Daniel A. Ermann, Emily K. Griffin et al. · Cureus · 2019 · 36 citations · Full text

Impact of academic medical center access on outcomes in multiple myeloma

Victoria A. Vardell, Daniel A. Ermann, Srinivas K. Tantravahi et al. · American Journal of Hematology · 2022 · 17 citations

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

William G. Wierda, Kathleen Dorritie, Jordan Gauthier et al. · Blood · 2024 · 16 citations · Full text

Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes

Charlotte B Wagner, Kenneth M. Boucher, Adrienne Nedved et al. · Haematologica · 2023 · 12 citations · Full text

A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.

Boyu Hu, Loretta J. Nastoupil, Houston Holmes et al. · Journal of Clinical Oncology · 2024 · 12 citations